(Q30829854)

English

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 June 2017

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial (English)

1 reference

Europe PubMed Central

26 June 2017

1 reference

based on heuristic

inferred from title

author name string

Dziadzio M

1

1 reference

Europe PubMed Central

26 June 2017

Denton CP

2

1 reference

Europe PubMed Central

26 June 2017

Smith R

3

1 reference

Europe PubMed Central

26 June 2017

Howell K

4

1 reference

Europe PubMed Central

26 June 2017

Blann A

5

1 reference

Europe PubMed Central

26 June 2017

Bowers E

6

1 reference

Europe PubMed Central

26 June 2017

Black CM

7

1 reference

Europe PubMed Central

26 June 2017

publication date

1 December 1999

1 reference

Europe PubMed Central

26 June 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

26 June 2017

42

1 reference

Europe PubMed Central

26 June 2017

12

1 reference

Europe PubMed Central

26 June 2017

2646-2655

1 reference

Europe PubMed Central

26 June 2017

Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Angiotensin receptor antagonists: focus on losartan

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Angiotensin converting enzyme inhibitors in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Pharmacotherapy of Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Is there circadian variation of plasma endothelin (ET-1) in patients with systemic scleroderma (SSc)?

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

The pathogenesis of pulmonary fibrosis: is there a fibrosis gene?

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28199912%2942%3A12%3C2646%3A%3AAID-ANR21%3E3.0.CO%3B2-T

21 January 2018

Identifiers

10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T

1 reference

Europe PubMed Central

26 June 2017

1 reference

Europe PubMed Central

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30829854&oldid=1582935135"